

February 15, 2024

Press Release

TOWA PHARMACEUTICAL CO., LTD.

Manufacturing and Marketing Approval for Three Ingredients and Eight Items

Towa Pharmaceutical Co., Ltd. (Head office: Kadoma, Osaka; President and Representative Director: Itsuro Yoshida) has been granted manufacturing and marketing approval for the following three ingredients and eight items of generics today:

<<Products for which manufacturing and marketing approval has been granted>>

1. ZONISAMIDE OD TABLETS 25mg

Therapeutic category	Parkinson's disease drug Parkinsonism in dementia with Lewy bodies (levodopa activator)
Product name	ZONISAMIDE OD TABLETS 25mg TRE "TOWA"
Brand-name drugs	TRERIEF OD Tablets 25mg

2. ZONISAMIDE OD TABLETS 50mg

Therapeutic category	Parkinson's disease drug (levodopa activator)
Product name	ZONISAMIDE OD TABLETS 50mg TRE "TOWA"
Brand-name drugs	TRERIEF OD Tablets 50mg

3. MICAFUNGIN SODIUM FOR INTRAVENOUS INFUSION

Therapeutic category	Candin antifungal agent
Product name	MICAFUNGIN SODIUM FOR INTRAVENOUS INFUSION 25mg / 50mg / 75mg "TOWA"
Brand-name drugs	Funguard 25mg / 50mg / 75mg for infusion

4. CEFCAPENE PIVOXIL HYDROCHLORIDE

Therapeutic category	Oral cephem antibiotic preparation
Product name	CEFCAPENE PIVOXIL HYDROCHLORIDE TABLETS 75mg / 100mg "TW" CEFCAPENE PIVOXIL HYDROCHLORIDE FINE GRANULES FOR PEDIATRIC 10% "TW"
Brand-name drugs	FLOMOX Tablets 75mg / 100mg FLOMOX Fine Granules for Pediatric 100mg

[Inquiries]

Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan

Tel: +81-6-6900-9102 / Fax: +81-6-7177-4960 / Email: kouhou@towayakuin.co.jp